COVID-19 Resources

COVID-19 Vaccine Information 

Ohio AAP COVID-19 Vaccine Update and Untruths

Ohio AAP/ODH Webinar on COVID-19 Vaccine for Children Recording

Ohio AAP/ODH Webinar on COVID-19 Vaccine for Children Slides

AAP COVID Vaccine Resources

Share the following information with your patients and their families to highlight the importance and safety of receiving the COVID vaccine! 

FAQs with Ohio AAP TIES Medical Director, Bob Frenck, MD, FAAP
(Click above to expand)

Why should you get the COVID vaccine?

While taking precautions such as wearing masks and maintaining social distance of 6 feet apart is effective in reducing the spread of COVID, completely stopping a pandemic requires using all tools available! The COVID vaccine works with your immune system to make sure your body will be ready to fight the virus if you are exposed. Using all available means, including the COVID vaccine will help us fight COVID and stop further spread. 

  1. What is the youngest age that will be able to receive any of the COVID-19 vaccines? Currently, the youngest is 12 years of age. However, we have been sent protocols from 2 different Sponsors with the age going down to 5 years of age. Some companies have talked about going down to 12 months or less, but no protocols have yet been sent.
  2. Any thoughts or predictions on WHEN we will start vaccinating kids? The clinical trials for children will likely start in late Winter to early Spring. In children, we are doing “Immunological bridging studies” – the numbers will be smaller and results available sooner (maybe within 2-3 months of enrolling). Thus, I still think it possible that we will have licensed vaccines for at least some pediatric age groups before the 2021-2022 school year.
  3. What about patients who have tested positive whether symptomatic or not OR have positive antibodies – is there a plan whether they will be able to receive the vaccine? Good question. That still needs to be decided. From small scale studies in adults, the frequency and type of side effects were the same whether or not you already had COVID-19.
  4. Where do Pediatricians fall in the distribution? I think all health care providers seeing patients are seen as a single category. But the final decisions will come from the State Health Departments. The decision will also partly depend on how many doses of vaccine are available.
  5. When will they use this same vaccine technology to come up with a universal influenza vaccine? That would be great! One thing in favor of the COVID-19 vaccine is that the spike protein seems to be essential to the virus. The essential protein for flu looks to be the stalk protein. However, it has been difficult to get a good antibody against the stalk protein. Maybe new technologies will improve our ability to make a vaccine against the stalk protein.
  6. Can you tell us more about the very low temperatures needed to keep the vaccines stable? Pfizer informed us that they are currently looking at the stability of the vaccine at warmer temps. My guess is we will find that the Pfizer vaccine will have storage requirements similar to Moderna. However, tests will need to be conducted to be sure.
  7. What temperatures are needed to store vaccines? Currently, Pfizer is listed as -70C, Moderna is -20C, and Astra Zeneca is refrigerated. However, I think companies will be looking at the ability to safely store the mRNA vaccines at warmer temps and there will be a workable solution as to the storage requirements.
  8. How do you recommend talking to families about potential long term risks that can’t be known yet due to the vaccine creation timeline? All the vaccines are targeting the spike protein. The mRNA vaccines are using mRNA that is degraded soon after it is translated into spike protein. So, there should not be any long term effects of the mRNA. The Astra Zeneca vaccine is using an adenovirus that is replication incompetent, meaning that the virus can’t live and grow in us. The Sanofi and NovaVax vaccines are protein vaccines, very similar to the flu vaccine. The end result is that while the technology is new, there is no evidence to indicate there is long term harm from the vaccine candidates.
  9. Are you concerned about how polarized the public is about science, especially prevention including vaccines? I am concerned about the general breakdown in the trust of science and how Public Health measures are being viewed as political issues instead of safety issues. However, we need to keep up the fight and continue to be strong advocates for the health of children, particularly preventive medicine such as vaccines. If we don’t keep up the campaign to educate and inform parents, we will be putting the health of children at risk. 

Email us if you don’t see your question already here!

True or False: Busting Myths about COVID-19 Vaccines

COVID Vaccination Communication Toolkits from the CDC: Designated toolkits for providers, clinics and more to educate and build vaccine confidence. 


Vaccine Hesitancy Resources 

COVID-19 Vaccine Hesitancy  General Vaccine Hesitancy  Background & History 

How to overcome COVID-19 vaccine hesitancy among Black patients

NPR You Can’t Treat If You Can’t Empathize  CDC Tuskegee Study 

BMJ- COVID-19 Vaccine Hesitancy Among Ethnic Minority Groups 

WebMD-Black Vaccine Hesitancy Rooted in Mistrust, Doubts Historical Origins of Tuskegee Experiment 
TIME- Distrust of New COVID Vaccines  USA Today- American has a History of Medically Abusing Black People  HISTORY Tuskegee Experiment
Psychiatric Times- Black Americans Distrust of COVID Vaccines  NEJM-Vaccine Distrust and Everyday Racism  NPR-In Tuskegee, Painful History Shadows Efforts To Vaccinate African Americans
NIH-COVID Related Medical Distrust  Battling Mistrust of Vaccines  Washington Post- Years of Medical Abuse Make Black Americans Less Likely to Trust COVID Vaccine 

Critical ODH COVID-19 Vaccine Updates

July 13, 2021: Updated COVID-19 Vaccination Provider Guidance: Health Equity Considerations
(Click above to expand)

To COVID-19 Vaccine Providers,

As Ohio’s COVID-19 vaccination program continues to evolve, the Ohio Department of Health (ODH) has posted an update to Provider Guidance: Health Equity Considerations on the Ohio COVID-19 Vaccine Providers’ webpage. This newly updated guidance offers strategies for vaccine providers to help reach our most vulnerable Ohioans who still need to be vaccinated.

We hope that you will implement some of the vaccination strategies and use the suggested messaging to the public included in the communication toolkits. The guidance also includes additional resources to help you reach as many vulnerable populations as possible and help bridge the gap in areas with low uptake of vaccine.

 If you have any questions or issues, please call the ODH Provider Call Center between 8 a.m. and 7 p.m. Monday through Friday at 1-844-9ODHVAX (1-844-963-4829) or email COVIDVACCINE@odh.ohio.gov.

Thank you for serving as a vaccination provider, and for your efforts to help protect Ohio’s most vulnerable residents.

Sincerely,

Ohio Department of Health COVID-19 Vaccination Provider Relations Team

June 29, 2021: Update, Tools and Resources on Adolescent COVID-19 Vaccination
(Click above to expand)

Health/Medical Association and Licensing Board Partners,

We want to share with you an update, tools and resources regarding COVID-19 vaccination of adolescents and young adults that we ask you to share with your members/licensees as you deem appropriate.

UPDATED RESOURCES AND GUIDANCE ABOUT COVID-19 VACCINATION RISK OF MYOCARDITIS/PERICARDITIS

Federal health agencies have updated COVID-19 vaccine resources for vaccine providers and vaccine recipients to include information about the risk of rare cases of myocarditis/pericarditis following mRNA COVID-19 vaccination, particularly in adolescents and young adults.

The U.S. Food & Drug Administration (FDA) has updated COVID-19 Vaccine Emergency Use Authorization fact sheets for the Pfizer and Moderna vaccines for patients and providers to include the risks of myocarditis and pericarditis following vaccination. In addition, the Centers for Disease Control and Prevention (CDC) has updated for providers its clinical considerations regarding myocarditis and pericarditis. These updates follow a review of information and a discussion by the CDC’s Advisory Committee on Immunization Practices last week. The FDA and CDC will continue to monitor reports, collect more information, and follow up to assess longer-term outcomes over several months.

The CDC continues to recommend COVID-19 vaccination for individuals 12 years of age and older, given the risk of COVID-19 illness and related, possibly severe complications such as long-term health problems, hospitalization, and death.

“Thanks to the extensive safety monitoring systems in the U.S., we can have confidence that we have the systems in place to identify this risk. These discussions are an example of the vaccine safety system working exactly as it should,” said Dr. Bruce Vanderhoff, Chief Medical Officer for the Ohio Department of Health.

Updated Resources for Vaccine Providers and Recipients

For each vaccine, the Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) has been revised to include a warning about myocarditis and pericarditis. The Fact Sheet for Recipients and Caregivers has been revised to include information about the risk of myocarditis and pericarditis and recommendations for providers.

The warning to vaccine recipients states:

  • Myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining outside the heart) have occurred in some people who have received the Pfizer or Moderna COVID-19 Vaccine.
  • In most of these people, symptoms began within a few days following receipt of the second dose of the vaccine.
  • The chance of having this occur is very low.
  • Vaccine recipients should seek medical attention right away if they have any of the following symptoms after receiving the vaccine:
    • Chest pain.
    • Shortness of breath.
    • Feelings of having a fast-beating, fluttering, or pounding heart.

Recommendations for clinicians:

  • Report all cases of myocarditis and pericarditis post COVID-19 vaccination to the Vaccine Adverse Event Reporting System (VAERS).
  • Consider myocarditis and pericarditis in adolescents or young adults with acute chest pain, shortness of breath, or palpitations. In this younger population, coronary events are less likely to be a source of these symptoms.
  • Ask about prior COVID-19 vaccination if you identify these symptoms, as well as relevant other medical, travel, and social history.
  • For initial evaluation, consider an ECG, troponin level, and inflammatory markers such as C-reactive protein and erythrocyte sedimentation rate. In the setting of normal ECG, troponin, and inflammatory markers, myocarditis or pericarditis are unlikely.
  • For suspected cases, consider consultation with cardiology for assistance with cardiac evaluation and management. Evaluation and management may vary depending on the patient age, clinical presentation, potential causes, or practice preference of the provider.
  • For follow-up of patients with myocarditis, consult the recommendations from the American Heart Association and the American College of Cardiology.
  • It is important to rule out other potential causes of myocarditis and pericarditis. Consider consultation with infectious disease and/or rheumatology specialists to assist in this evaluation.
    • Where available, evaluate for potential causes of myocarditis and pericarditis, particularly acute COVID-19 infection (e.g., PCR testing), prior SARS-CoV-2 infection (e.g., detection of SARS-CoV-2 nucleocapsid antibodies), and other viral etiologies (e.g., enterovirus PCR and comprehensive respiratory viral pathogen testing).

More Information/Resources

Background: Myocarditis/Pericarditis Reports

Since April 2021, there have been more than 1,000 reports to VAERS of cases of myocarditis and pericarditis after mRNA COVID-19 vaccination (i.e., Pfizer-BioNTech, Moderna) in the United States. However, not all cases have been verified. The CDC is evaluating 484 total reported cases, 323 of which meet the CDC working case definition for myocarditis or pericarditis. All of these cases were among vaccine recipients younger than 30.

CDC notes that these reports are rare given the millions of COVID-19 vaccine doses administered. Confirmed cases have occurred:

  • Mostly in male adolescents and young adults age 16 years or older.
  • More often following the second dose (vs. the first dose) of an mRNA COVID-19 vaccine.
  • Typically, within several days after COVID-19 vaccination.
  • Most patients who received care responded well to treatment and rest and quickly felt better. Patients can usually return to normal daily activities after symptoms improve, but they should talk with their doctor about returning to exercise or sports.

Joint Statement

The American Academy of Pediatrics, the American Academy of Family Physicians, the American Medical Association, the American College of Physicians, the American Heart Association, and several other organizations have joined the CDC in issuing a joint statement on COVID-19 vaccination and myocarditis/pericarditis.

“The facts are clear: this is an extremely rare side effect, and only an exceedingly small number of people will experience it after vaccination. Importantly, for the young people who do, most cases are mild, and individuals recover often on their own or with minimal treatment. In addition, we know that myocarditis and pericarditis are much more common if you get COVID-19, and the risks to the heart from COVID-19 infection can be more severe,” according to the statement. 

YOUTH VACCINATION CLINIC PLANNING AND COMMUNICATIONS TOOLKIT

 The Ohio Department of Health has developed a toolkit for use in planning and communicating COVID-19 youth vaccination clinics which is available on the state’s coronavirus website at

 https://coronavirus.ohio.gov/static/vaccine/youth-clinic-toolkit.pdf. The toolkit includes talking points, language tips, an FAQ for parents, guardians and eligible youth, myths vs. facts, vaccine clinic planning checklist, graphics for posters and signs, sample social media posts, and other resources.

NEW PUBLIC SERVICE ANNOUNCEMENT SPOT ABOUT YOUTH COVID-19 VACCINATION

The Ohio Department of Health (ODH) has produced a new COVID-19 vaccination public service announcement in cooperation with several other partners titled “Pediatricians and Parents” that we ask you to consider sharing on your social media platforms and in other communication that may reach parents of youth ages 12-17 who are eligible for vaccination with the Pfizer vaccine. The PSA is posted on ODH’s YouTube channel at https://www.youtube.com/watch?v=CRtlzTJ43oA.

May 19, 2021: Important Update from ODH on New COVID-19 Vaccine Ordering Process
(Click above to expand)

To all enrolled provider health centers and pediatricians,

Effective Monday, May 24, all Ohio federally qualified health centers and pediatricians enrolled as COVID-19 vaccine providers will be required to directly order COVID-19 vaccine doses each week using the Vaccine Ordering Management System (VOMS). This includes first and second doses of the Pfizer and Moderna products, as well as the single-dose Johnson & Johnson (Janssen vaccine).

HOW TO ORDER VACCINE DOSES

Minimum order quantities

  • Pfizer two-dose vaccine:30 doses (available in increments of 30) shipped from the Ohio Department of Health Receipt, Store, and Stage (RSS) warehouse.
  • Moderna two-dose vaccine:100 doses (available in increments of 100) shipped from McKesson.
  • Johnson & Johnson single-dose vaccine:100 doses (available in increments of 100) shipped from McKesson.

Ordering timeline/window

As a first step in this transition, providers will have two ordering windows each week for delivery the following week. 

  • The first ordering window opens Mondays at 8 a.m. and closes Thursdays at noon. These orders would be delivered from McKesson the following Monday or Tuesday, or from the RSS on Tuesday.
  • The second ordering window opens Fridays at noon and closes Sundays at noon. These orders would be delivered from McKesson the following Tuesday or Wednesday, or from the RSS the following Thursday.

Orders requested outside of these two windows cannot be accepted. Ordering timelines and deadlines may be adjusted in the future as needed.

Providers can place first-dose and second-dose orders in a single order or in separate orders at their discretion. Providers should use their own internal processes for tracking first-dose and second-dose inventory.

HOW TO PLACE AN ORDER

Note, it may be necessary to reconcile your inventory before ordering. Reconciling only your COVID-19 vaccine is acceptable.

  1. Log into your VOMS account.
  2. Select your site (if applicable).
  3. Click Orders & Returns in the left navigation menu.
  4. Click Orders & Transfers.
  5. Click New Order.
  6. Choose Order Set.
    • COVID19 — Pfizer 30 
  • Select this order set to request Pfizer quantities of 360 doses or fewer.
  • Minimum order quantity is 30 doses.
  • This special ordering option is available only for a limited number of vaccine providers including health centers and pediatricians.
    • COVID19 — Moderna 
  • Select this order set to request Moderna vaccine.
  • Minimum order quantity is 100 doses.
    • COVID19 — Janssen
  • Select this order set to request Johnson & Johnson (Janssen) vaccine.
  • Minimum order quantity is 100 doses.
  1. Input your order.
    • Enter the total quantity of doses needed in the “Doses Requested” field
    • Enter high and low temperatures for your vaccine storage unit in the Comments box.Moderna orders will need freezer and refrigerator temperatures.
    • Enter any additional notes for ODH, such as requests for a special clinic or event. Providers can also use the Comments box for internal notes or reminders for that order.
    • Click Next.
  2. Verify your location’s shipping address, contact information, and delivery hours. If any information is incorrect, please contact the ODH Immunization Program team at the email address listed below.
  3. Click Submit Order.

ORDERING EXPECTATIONS

Please order only the quantity you need for the following week. You will have the opportunity to order doses on a weekly basis. 

Contact us

If you are unable to make either training session and would like information about additional training opportunities or if you need additional time to complete this transition, we can work out a plan with you. Please contact the ODH vaccine allocations team by emailing  COVIDVACCINE@odh.ohio.gov using the subject line Ordering in VOMS. 

If you have any additional questions, please call the ODH Provider Call Center between 8 a.m. – 7 p.m. Monday through Friday, and 8 a.m. – 5 p.m. Saturday and Sunday, at 1-844-9ODHVAX (1-844-963-4829) or email COVIDVACCINE@odh.ohio.gov.

We look forward to assisting you during this transition.

Sincerely,

Ohio Department of Health

Bureau of Infectious Diseases

Immunization Program

For information about COVID-19:
coronavirus.ohio.gov
1-833-4-ASK-ODH

March 9, 2021: Phase 2A Guidance for Providers
(Click above to expand)

Ohio is expanding eligibility for the COVID-19 vaccine as supply is increasing, and as vaccinations for previously defined priority populations continue. Phase 2A, which began March 4, 2021, includes expanded eligibility for Ohioans based upon age. Phase 2A opened vaccination based on age, beginning with individuals age 60 and older, because the risk of more severe reactions and outcomes from COVID-19 increases with age. Who may be vaccinated during Phase 2A? This opens eligibility to approximately 695,000 eligible Ohioans. Eligible individuals can receive a vaccine from the provider of their choice. AGE ELIGIBILITY Individuals age 60 and older. Individuals age 65 and older previously eligible under Phase 1B who have not yet received the vaccine remain eligible. Who will be offering Phase 2A vaccinations? Eligible vaccine recipients may receive a COVID-19 vaccination from a provider of their choice, including local health departments, hospitals, retail and independent pharmacies, and federally qualified health centers. Additional providers will continue to be added as vaccine supply increases. How to help Ohioans find vaccine providers, schedule appointments Vaccine providers are asked to participate in two services to help Ohioans looking for a streamlined approach to finding a provider and scheduling an appointment. • Vaccine Management Solution (VMS) – This one-stop solution for patients beginning the vaccination process allows Ohioans to determine eligibility, schedule appointments, submit health information, and receive updates and reminders. Public access to the web-based program began March 8, 2021. o All Ohioans can use the tool to determine eligibility and see existing allocated providers. During the initial phase, eligible Ohioans in several areas can book an appointment directly within the VMS tool. o Providers will be required to either report vaccines administered via the VMS scheduling system or an electronic health record (EHR) that interfaces with the state’s VMS system, no later than the week of March 22. The state anticipates this will enhance the customer service experience for Ohioans, reduce data lags, and provide real-time information on vaccination progress at the state and county level. o Full booking functionality will expand as more providers adopt the system or integrate with VMS. As vaccines become more widely available and providers conclude vaccinating patients who still need their second dose, the program will allow direct scheduling statewide. o VMS will be used for scheduling appointments at Ohio’s mass vaccination sites. o Vaccine providers who are receiving allocations but have not received an invitation to join VMS are asked to call the ODH Provider Call Center at 1-844-9ODHVAX (1-844-963-4829) or email COVIDVACCINE@odh.ohio.gov

Call Center at 1-844-9ODHVAX (1-844-963-4829) or email COVIDVACCINE@odh.ohio.gov

February 16, 2021: COVID-19 Vaccine Town Halls for At-Risk Populations to Address Vaccine Hesitancy
(Click above to expand)

Health/Medical/Public Health/Pharmacy/Health Plan/Long-Term Care Association Partners,

The Ohio Department of Health and the Ohio Department of Mental Health and Addiction Services have scheduled a series of COVID-19 Vaccine Town Halls with medical experts, community leaders, and public health professionals to address common concerns and questions among specific populations. As Ohio continues to roll out the COVID-19 vaccine, sharing accurate, reliable information with at-risk populations to help reduce vaccine hesitancy remains a high priority.

We are asking for your help by sharing this information with your members and encouraging them to promote these Town Halls with their patients/stakeholders.

A toolkit is available for download to help promote the Town Halls at https://coronavirus.ohio.gov/static/vaccine/town_hall_communications_toolkit.pdf. In addition, a graphics package of web banners, fliers, social media graphics, and web advertisements is linked within the toolkit and is accessible here.

 The Town Hall schedule for at-risk populations is as follows:

  • Monday, February 22, 6:30 p.m. – African American Ohioans
  • Tuesday, Feb. 23, 6:30 p.m. – Hispanic/Latino Ohioans
  • Monday, March 1, 6:30 p.m. – Asian American and Pacific Islander Ohioans
  • Tuesday, March 2, 6:30 p.m. – Rural Ohioans

Thank you for your assistance in spreading the word about these Town Halls so that we can share accurate, reliable information with at-risk populations to help reduce vaccine hesitancy.

Regards,

Russ Kennedy

Deputy Director for External Affairs

January 14, 2021: Enrolled COVID-19 Vaccination Providers Webinar re Phase 1B Overview
(Click above to expand)

Thank you for joining the Ohio Department of Health (ODH) on Monday, January 11 for a webinar to give Ohio’s 2,000+ enrolled vaccination providers an overview of our Phase 1B vaccination strategy and the important role that many of you will play in vaccinating priority populations. A guidance document is attached outlining what providers need to know about Phase 1B of COVID-19 vaccine distribution.

Phase 1B starts next week (week of January 18). If you were not able to attend the webinar, it is critical that you watch a recording to learn what role you may play as a vaccination provider in Phase 1B and expectations of you.

The recording is available at https://cisco.webex.com/recordingservice/sites/cisco/recording/5732bceb03384d0e946774784bda85fe/playback. You may receive a message about downloading/decrypting taking a few moments. Afterward, although the screen will read “There is no content to view at the moment..” press the “play” button on the toolbar in the lower left corner of the screen. It will take about 12 seconds before the webinar moderator begins to speak.

In addition to the recording, the following resources are linked below: 

The webinar invitation was sent to each enrolled provider’s primary contact person and backup contact person designated at enrollment. Because of the importance of this communication, we are sending this post-webinar email and information to these individuals, as well as to provider leadership contacts identified on enrollment applications.

Highlights from the webinar include:

  • Phase 1B starts the week of January 18 and will focus on vaccinating Ohioans age 80 and older.
    • Five-year age groups will be phased in each week thereafter (i.e., 75+, 70+, and 65+).
    • Individuals age 18 and older (Moderna vaccine) or age 16 and older (Pfizer-BioNTech vaccine) with severe congenital, developmental, or early onset medical disorders that make them particularly vulnerable will be eligible for vaccination beginning the week of January 25.
    • K-12 teachers and staff in schools that commit to returning to full in-class or hybrid learning by March 1 will be eligible for vaccination beginning the week of February 1.
  • Not all Phase 1B providers will be allocated vaccine initially, and allocations will be made on a rolling basis as vaccine becomes available.
  • Providers who will receive a vaccine shipment the week of January 18 received an email notification (including number of doses) on Tuesday, January 12. The email was sent to the primary contact person your enrolled site(s) designated on its/their enrollment application.
    • These shipments will arrive between Monday and Wednesday, January 18 – 20.
  • For future vaccine shipments, providers who will receive additional vaccine will get an email notification from ODH in advance. This email will be sent to the primary contact person and backup contact person your enrolled site(s) designated on its/their enrollment application.
  • The number of doses allocated to providers will be limited while the vaccine supply remains limited.
  • Providers receiving vaccine are expected to be prepared to start administering it within 24 hours of receipt.
  • Providers are expected to use all of their vaccine supply within 7 days of receipt.
  • Allocations were made based on Phase 1B population (80+ year olds) within the county – and vaccines should be administered in the same county.
  • It is ODH’s expectation that providers make vaccine available to the public, e.g., do not only provide vaccine to your existing patient panel.
  • The state is adding a search function on its coronavirus website so eligible Ohioans can find where to get vaccinated.
    • Providers must submit vaccine administration location addresses, phone numbers, and website to the state by logging into their OHID account (same account used to enroll as a COVID-19 vaccination provider) at http://bit.ly/SubmitProviderLocation
  • A broad range of COVID-19 vaccination training materials, tools, and resources are available on the ODH website at https://odh.ohio.gov/wps/portal/gov/odh/know-our-programs/covid-19-vaccine-provider/covid-19-vaccine-provider-training.

Please watch the webinar for more detailed information about these and other issues.

January 13, 2021: Share Your Information for New COVID-19 Vaccine Provider Directory
(Click above to expand)

To Enrolled Vaccine Provider Partners,

This is a reminder that your urgent action is required to be included in a new statewide COVID-19 vaccine provider search that will be available at coronavirus.ohio.gov/vaccine beginning tomorrow, Jan. 14.

To provide your contact information for the new Vaccine Provider Locations directory, click here.

This vital new resource will help Ohioans eligible to receive vaccine during Phase 1B  locate a provider in their area. The directory will show all enrolled COVID-19 vaccination providers currently administering vaccines to Phase 1B populations throughout Ohio. The public will be able to search for a provider by county, ZIP code, or category.

HOW TO SUBMIT YOUR INFORMATION

Complete this brief form at https://ohid.ohio.gov/wps/myportal/gov/covidvac/locations/vaccine-administration. This is a part of the Vaccination Provider Program (COVID-19) app.

Step-by-step instructions:

  1. Click on the form link. This will prompt you to log into your OHID account.
    • This is the account you created to enroll as a vaccine provider.
    • If you are a new user, create an account, and request access to the Vaccination Program (COVID-19) application to begin enrollment as a vaccine provider.
  2. Once you land on the Vaccine Administration Locations page, click the Add Location(s) form.
  3. Click on your name and Terminal Distributor of Dangerous Drugs (TDDD) license number in the dropdown menu.
    • To find your (TDDD) license number, please visit the State of Ohio Board of Pharmacy website.
    • If you cannot find your name and (TDDD) in the dropdown, you must complete and submit a Section A and Section B form to complete enrollment as a vaccine provider. Once your Section B form is reviewed, and enrollment is complete, your facility will appear in the dropdown for this form.
  4. Enter the following information:
    • Name of vaccine administration site.
    • Address of vaccine administration location, including city, ZIP code, and county. (Note, this is the address of the location the public will go to receive the vaccination, not the shipment address.)
    • Phone number(s) for patients to call to schedule a vaccine appointment if eligible.
    • Website for patients to schedule an appointment or find more information.
    • If you need to add other locations, click the Add Another Location button. Repeat the process above for all administration sites.
    • Click Submit Location(s) Entries.

If you have any technical issues accessing your OHID account or completing the process above, contact the Office of Management Information Systems (OMIS) Help Desk at HelpStar@odh.ohio.gov or 614-752-5190.

For other inquiries, please call the ODH Provider Call Center between 8  a.m. – 7 p.m. Monday through Friday, and 8 a.m. – 5 p.m. Saturday and Sunday, at 1-844-9ODHVAX (1-844-963-4829) or email COVIDVACCINE@odh.ohio.gov. You also may visit the ODH COVID-19 Vaccine Provider Information Training page for additional information and resources

January 7, 2021: Ensuring the COVID-19 Vaccine is Not Wasted
(Click above to expand)

Enrolled COVID-19 Vaccination Provider Partners,

The Ohio Department of Health (ODH) offers the following additional guidance for ensuring COVID-19 vaccine is not wasted. In order to mitigate the risk of wasting COVID-19 vaccine, providers should attempt to verify the number of vaccine recipients immediately prior to each scheduled clinic.

To prevent vaccine wastage in the event that you have excess vaccines upon completion of a vaccination clinic and those vaccines are set to expire, it is critically important that providers have a plan in place to immediately identify and administer vaccine to backup recipients. Many providers have implemented waiting lists of eligible individuals for such circumstances.

To the extent possible, ODH advises that providers administer excess vaccines in the following priority order:

  1. Identify Phase 1A eligible individuals to administer the vaccine to (healthcare providers, EMS personnel, or congregate care residents/staff).
  2. Identify Phase 1B eligible individuals to administer the vaccine to (individuals age 65+, people with severe congenital, developmental, or early onset medical disorders that make them particularly vulnerable, and teachers/staff in K–12 schools that plan to return to in-person classes in March).
  3. Identify otherwise eligible adults not included in Phases 1A or 1B to administer the vaccine to (e.g., priority to adults with underlying medical conditions before adults with no underlying medical conditions).
  4. If more than 20 doses are at risk of wastage, please call the ODH Provider Call Center at the number below to discuss options including, but not limited to, transfer of vaccine to other enrolled providers.

 IMPORTANT:  To prevent wastage of COVID-19 vaccine, providers should have a backup recipient plan in place. Where possible, follow the priority guidance outlined above. When not possible due to time constraints or lack of availability of priority individuals, please administer vaccine to any individuals eligible under the appropriate FDA Emergency Use Authorization (EUA).

As noted in previous guidance on this issue, if you administer vaccinations under the circumstances outlined above:

  • The vaccine administration must be reported in ImpactSIIS, including race and ethnicity data, within 24 hours.
  • Target population/occupation data does not need to be reported for vaccinated individuals not in Phase 1A.
  • Be sure to include these vaccinated individuals in your follow-up plans for administering second doses.

If you have any questions or issues, please call the ODH Provider Call Center between 8:00 a.m. – 7:00 p.m. Monday through Friday, and 8:00 a.m. – 5:00 p.m. Saturday and Sunday, at 1-844-9ODHVAX (1-844-963-4829) or email COVIDVACCINE@odh.ohio.gov. You also may visit the ODH COVID-19 Vaccine Provider Information Training page for additional information and resources

Sincerely,

ODH COVID-19 Vaccination Provider Relations Team


Ohio AAP COVID-19 Webinars & Podcasts

For Providers


Immunization Resources


For Parents 

For School Nurses, Childcare Providers, and Staff